Moss Adams Wealth Advisors LLC Has $290,000 Stock Position in Stryker Co. (NYSE:SYK)

Moss Adams Wealth Advisors LLC boosted its position in Stryker Co. (NYSE:SYK) by 6.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 803 shares of the medical technology company’s stock after buying an additional 52 shares during the quarter. Moss Adams Wealth Advisors LLC’s holdings in Stryker were worth $290,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Edgestream Partners L.P. bought a new stake in Stryker during the 2nd quarter valued at approximately $369,000. AE Wealth Management LLC lifted its position in shares of Stryker by 101.8% in the 2nd quarter. AE Wealth Management LLC now owns 3,414 shares of the medical technology company’s stock worth $1,162,000 after acquiring an additional 1,722 shares during the period. Pacer Advisors Inc. boosted its stake in Stryker by 8.4% during the second quarter. Pacer Advisors Inc. now owns 27,438 shares of the medical technology company’s stock worth $9,336,000 after buying an additional 2,122 shares in the last quarter. Sei Investments Co. boosted its position in shares of Stryker by 4.0% during the 2nd quarter. Sei Investments Co. now owns 168,336 shares of the medical technology company’s stock valued at $57,271,000 after acquiring an additional 6,443 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Stryker by 69.7% in the second quarter. Thrivent Financial for Lutherans now owns 87,244 shares of the medical technology company’s stock valued at $29,685,000 after acquiring an additional 35,833 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $383.91 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $146.35 billion, a P/E ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95. The business has a 50-day moving average of $375.51 and a 200-day moving average of $358.81. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the previous year, the company earned $2.46 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is currently 36.01%.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on SYK shares. Truist Financial boosted their price objective on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Wells Fargo & Company upped their price objective on Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. UBS Group increased their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Barclays boosted their target price on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.